Grace & White Inc’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.39M Hold
29,000
0.22% 78
2026
Q1
$1.07M Hold
29,000
0.19% 86
2025
Q4
$1.48M Hold
29,000
0.26% 75
2025
Q3
$1.61M Hold
29,000
0.28% 74
2025
Q2
$2M Hold
29,000
0.37% 65
2025
Q1
$2.01M Hold
29,000
0.38% 62
2024
Q4
$2.49M Hold
29,000
0.47% 56
2024
Q3
$3.45M Hold
29,000
0.62% 43
2024
Q2
$4.14M Sell
29,000
-4,000
-12% -$530K 0.78% 39
2024
Q1
$4.24M Hold
33,000
0.76% 38
2023
Q4
$3.41M Hold
33,000
0.6% 52
2023
Q3
$3M Hold
33,000
0.56% 54
2023
Q2
$2.67M Buy
33,000
+22,000
+200% +$1.8M 0.49% 56
2023
Q1
$875K Buy
+11,000
New +$780K 0.17% 89

Other funds holding NVO

Grace & White Inc's NVO Position: Q2 2026 in Review

Grace & White Inc held its Novo Nordisk (NVO) position steady in Q2 2026 at 29,000 shares worth $1.39M. The position accounts for 0.22% of the portfolio, ranked #78.

Grace & White Inc first reported a position in NVO in Q1 2023 and has held it in 14 quarters since. The position peaked at $4.24M in Q1 2024. 240 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Grace & White Inc held 29,000 shares of Novo Nordisk worth $1.39M as of Q2 2026.
  • Grace & White Inc left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.22% of Grace & White Inc's portfolio in Q2 2026, its #78 holding.
  • Grace & White Inc first reported a position in Novo Nordisk in Q1 2023 and has held it in 14 quarters since.
  • Grace & White Inc's Novo Nordisk position peaked at $4.24M in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Grace & White Inc's 13F filing for Q2 2026, filed 17 Jul 2026.